Drug Trial Radar · NCT05535244
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Oct 17, 2022
Primary completion
Feb 26, 2027
Study completion Feb 26, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Conditions
- Multiple Myeloma
Interventions
CevostamabDrug
Cevostamab will be administered by IV infusion in 21-day cycles.
TocilizumabDrug
Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) as Determined by the InvestigatorTime frame: Baseline up to approximately 2 years
- Percentage of Participants with Adverse EventsTime frame: Baseline up to approximately 2 years
Locations
27 sites in 8 countries. Site status is shown where the registry gives one.
University of Colorado
Aurora, Colorado
Mayo Clinic-Jacksonville
Jacksonville, Florida
University of Maryland Greenebaum Cancer Center
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic - Rochester
Rochester, Minnesota
Icahn School of Medicine at Mount Sinai (ISMMS)
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Tennessee Oncology - Nashville
Nashville, Tennessee
Hunstman Cancer Institute
Salt Lake City, Utah
Calvary Mater Newcastle
Waratah, New South Wales, Australia
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia
UZ Leuven Gasthuisberg
Leuven, Belgium
CHU NANTES - Hôtel Dieu
Nantes, France
APHP - Hospital Saint Louis
Paris, France
CHU de Poitiers - La Miletrie
Poitiers, France
Klinik der Uni zu Köln
Cologne, Germany
Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II
Hamburg, Germany
Universitätsklinikum Würzburg
Würzburg, Germany
Hadassah Ein Karem Hospital
Jerusalem, Israel
Sheba Medical Center
Ramat Gan, Israel
Sourasky Medical Centre
Tel Aviv, Israel
Policlinico S.Orsola-Malpighi
Bologna, Emilia-Romagna, Italy
Asst Papa Giovanni Xxiii
Bergamo, Lombardy, Italy
Fond. IRCCS Istituto Nazionale Tumori
Milan, Lombardy, Italy
A.O. Città della Salute e della Scienza D - Osp. S. Giov. Battista Molinette
Turin, Piedmont, Italy
Hospital Clínic i Provincial
Barcelona, Spain
Hospital Univ. 12 de Octubre
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.